Glucocorticoids are potent anti-inflammatory agents that are widely used for the treatment of many inflammatory, autoimmune, and neoplastic disorders. However, their beneficial effect is associated with several side effects, including an increased risk of cardiovascular complications, such as myocardial infarction and stroke. Whether their use also contributes to a procoagulant state, and therefore increases the risk of venous thromboembolism (VTE), is still a matter of debate. As an increased risk of venous thrombotic events is described in patients with Cushing's syndrome, which is characterized by endogenous hypercortisolism, it is reasonable to speculate that the chronic administration of glucocorticoids may induce a hypercoagulable state. However, it seems virtually impossible to separate the role of the drug from the underlying condition, which itself predisposes to the development of VTE. Actually, some evidence suggests that the use of exogenous glucocorticoids for the treatment of underlying disease and its exacerbations may further amplify the risk of VTE. Moreover, a procoagulant state has also been reported in healthy participants receiving oral glucocorticoids versus placebo. We have performed a concise narrative review on available data on the influence of exogenous glucocorticoids on hemostasis and their clinical impact on the risk of VTE.

糖皮质激素是有效的抗炎剂，广泛用于治疗许多炎症、自身免疫和肿瘤性疾病。然而，它们的有益作用与一些副作用有关，包括增加心血管并发症的风险，如心肌梗塞和中风。它们的使用是否也有助于促凝状态，从而增加静脉血栓栓塞 (VTE) 的风险，仍然存在争议。由于库欣综合征患者静脉血栓形成事件的风险增加，其特征是内源性皮质醇增多症，因此推测长期使用糖皮质激素可能会导致高凝状态是合理的。然而，似乎几乎不可能将药物的作用与潜在疾病分开，这本身就有利于VTE的发展。实际上，一些证据表明，使用外源性糖皮质激素治疗潜在疾病及其恶化可能会进一步放大 VTE 的风险。此外，与安慰剂相比，接受口服糖皮质激素的健康参与者也报告了促凝状态。我们对有关外源性糖皮质激素对止血的影响及其对 VTE 风险的临床影响的现有数据进行了简明的叙述性审查。与安慰剂相比，接受口服糖皮质激素的健康参与者也报告了促凝状态。我们对有关外源性糖皮质激素对止血的影响及其对 VTE 风险的临床影响的现有数据进行了简明的叙述性审查。与安慰剂相比，接受口服糖皮质激素的健康参与者也报告了促凝状态。我们对有关外源性糖皮质激素对止血的影响及其对 VTE 风险的临床影响的现有数据进行了简明的叙述性审查。